Literature DB >> 27853625

Targeting of slug sensitizes anaplastic thyroid carcinoma SW1736 cells to doxorubicin via PUMA upregulation.

Anbing Dong1, Xuelong Jiao2, Dong Chen2, Fengyun Hao2, Kejun Zhang1.   

Abstract

OBJECTIVE: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers and often shows resistance to multimodal therapeutic approaches. It has been shown that the transcriptional repressor Slug inhibits the chemotherapeutic agent-induced apoptosis of cancer cells. We evaluated whether targeting of Slug could augment doxorubicin (DOX)-induced apoptosis of ATC cells. We also determined changes in PUMA (p53-upregulated modulator of apoptosis) expression levels to identify possible mechanisms of their combined actions. Methods SW1736 cells were transfected with Slug siRNA or/and PUMA siRNA and then exposed to DOX (0.1, 1, and 5 mM) for selected times. Scrambled siRNA was used as a control. The effects on cell viability were determined via MTT assay. Apoptosis was assessed using TUNEL assays and annexin V staining, and was confirmed by flow cytometry analyses. Slug and PUMA levels were determined using western blotting and immunofluorescence analyses. We used a subcutaneous implanted tumor model of SW1736 cells in nude mice to assess the effects of Slug silencing in combination with DOX on tumor development. Apoptosis was assessed via TUNEL assay. Results Targeting of Slug using siRNA combined with DOX led to lower cell viability than treatment with DOX alone in SW1736 cells. TUNEL and flow cytometry analyses showed that targeting of Slug enhanced DOX-induced apoptosis of SW1736 cells. In addition, targeting of Slug increased PUMA expression, and targeting of PUMA restored the chemoresistance of SW1736/Slug siRNA cells to DOX. Conclusions Knockdown of Slug enhanced the antitumor activity of DOX in SW1736 cells via induction of PUMA upregulation. Our results suggest that targeting of Slug has good potential for the development of new therapeutic strategies for ATC.

Entities:  

Keywords:  Anaplastic thyroid carcinoma; PUMA; chemotherapy; slug

Year:  2016        PMID: 27853625      PMCID: PMC5107651     

Source DB:  PubMed          Journal:  Int J Biochem Mol Biol        ISSN: 2152-4114


  19 in total

1.  SNAI2 as a novel radioprotector of normal tissue by gene transfer using a lentiviral bicistronic SIN vector.

Authors:  Patrick Maier; Carsten Herskind; David Barzan; W Jens Zeller; Frederik Wenz
Journal:  Radiat Res       Date:  2010-05       Impact factor: 2.841

2.  Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review.

Authors:  Eric J Sherman; Su Hsien Lim; Alan L Ho; Ronald A Ghossein; Matthew G Fury; Ashok R Shaha; Michael Rivera; Oscar Lin; Suzanne Wolden; Nancy Y Lee; David G Pfister
Journal:  Radiother Oncol       Date:  2011-10-06       Impact factor: 6.280

3.  Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.

Authors:  K B Ain; M J Egorin; P A DeSimone
Journal:  Thyroid       Date:  2000-07       Impact factor: 6.568

4.  Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.

Authors:  Darya Buehler; Heather Hardin; Weihua Shan; Celina Montemayor-Garcia; Patrick S Rush; Sofia Asioli; Herbert Chen; Ricardo V Lloyd
Journal:  Mod Pathol       Date:  2012-08-17       Impact factor: 7.842

5.  SLUG (SNAI2) overexpression in embryonic development.

Authors:  P A Pérez-Mancera; I González-Herrero; K Maclean; A M Turner; M-Y Yip; M Sánchez-Martín; J L García; C Robledo; T Flores; A Gutiérrez-Adán; B Pintado; I Sánchez-García
Journal:  Cytogenet Genome Res       Date:  2006       Impact factor: 1.636

Review 6.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Authors:  R C Smallridge; J A Copland
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-24       Impact factor: 4.126

7.  Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis.

Authors:  Chang-Rong Wei; Jun Liu; Xiao-Jun Yu
Journal:  Int J Clin Exp Med       Date:  2015-12-15

8.  Anaplastic thyroid carcinoma: risk factors and outcome.

Authors:  J G Demeter; S A De Jong; A M Lawrence; E Paloyan
Journal:  Surgery       Date:  1991-12       Impact factor: 3.982

9.  RNA interference targeting slug increases cholangiocarcinoma cell sensitivity to cisplatin via upregulating PUMA.

Authors:  Kejun Zhang; Dong Chen; Xingang Wang; Shaoyan Zhang; Jigang Wang; Yuan Gao; Bomin Yan
Journal:  Int J Mol Sci       Date:  2011-01-14       Impact factor: 5.923

10.  SFRP2 and slug contribute to cellular resistance to apoptosis in hypertrophic scars.

Authors:  Liang Chen; Zhenxiang Wang; Shirong Li; Guangjian Zhao; Maosheng Tian; Zhicheng Sun
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

View more
  1 in total

1.  Effect of Slug-Mediated Down-Regulation of E-Cadherin on Invasiveness and Metastasis of Anaplastic Thyroid Cancer Cells.

Authors:  Li Sheng; Shanjuan Zhang; Hui Xu
Journal:  Med Sci Monit       Date:  2017-01-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.